Anti-drug Antibody Validation Testing and Reporting Harmonization
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Springer Nature in The AAPS Journal
- Vol. 24 (1) , 1-23
Abstract
Evolving immunogenicity assay performance expectations and a lack of harmonized anti-drug antibody validation testing and reporting tools have resulted in significant time spent by health authorities and sponsors on resolving filing queries. Following debate at the American Association of Pharmaceutical Sciences National Biotechnology Conference, a group was formed to address these gaps. Over the last 3 years, 44 members from 29 organizations (including 5 members from Europe and 10 members from FDA) discussed gaps in understanding immunogenicity assay requirements and have developed harmonization tools for use by industry scientists to facilitate filings to health authorities. Herein, this team provides testing and reporting strategies and tools for the following assessments: (1) pre-study validation cut point; (2) in-study cut points, including procedures for applying cut points to mixed populations; (3) system suitability control criteria for in-study plate acceptance; (4) assay sensitivity, including the selection of an appropriate low positive control; (5) specificity, including drug and target tolerance; (6) sample stability that reflects sample storage and handling conditions; (7) assay selectivity to matrix components, including hemolytic, lipemic, and disease state matrices; (8) domain specificity for multi-domain therapeutics; (9) and minimum required dilution and extraction-based sample processing for titer reporting. Graphical AbstractKeywords
This publication has 39 references indexed in Scilit:
- Statistical methods and tool for cut point analysis in immunogenicity assaysJournal of Immunological Methods, 2013
- Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on PharmacokineticsThe AAPS Journal, 2012
- Statistical considerations for calculation of immunogenicity screening assay cut pointsJournal of Immunological Methods, 2011
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISARegulatory Toxicology and Pharmacology, 2007
- An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drugJournal of Immunological Methods, 2007
- Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic proteinJournal of Immunological Methods, 2006
- An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigenJournal of Immunological Methods, 2005
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004